Summary
The provided AI claims are largely about pricing, generic availability, and assistance programs, none of which are supported by the supplied FDA prescribing information excerpts. No on-label medical labeling content (indications, dosing, contraindications, warnings/precautions, adverse reactions, etc.) is evaluated by these claims, preventing on-label alignment assessment.
Category Scores
Accurate Statements
Unsupported Statements
Tigecycline (Tygacil) is an intravenous antibiotic for complicated infections.
The provided label excerpts do not include an indication statement or route/dosing description supporting 'intravenous antibiotic for complicated infections.'
Generic versions of tigecycline have been available since 2020.
Not supported by the provided prescribing information excerpts.
The availability of generic tigecycline lowered costs compared to the branded product.
Not addressed in the provided prescribing information excerpts.
Discounts for tigecycline are accessible now through patient assistance programs, manufacturer coupons, and pharmacy discount cards.
Not supported by the provided prescribing information excerpts.
Pfizer’s partnership with America’s Health Insurance Plans offers copay savings for eligible commercially insured patients.
Not supported by the provided prescribing information excerpts.
The copay savings cap out-of-pocket costs at $25 per dose (up to a yearly maximum).
Not supported by the provided prescribing information excerpts.
Pfizer’s Tygacil Savings Card provides instant rebates at pharmacies for eligible patients.
Not supported by the provided prescribing information excerpts.
Tygacil Savings Card can be applied for online or via phone (1-855-984-6302).
Not supported by the provided prescribing information excerpts.
GoodRx lists tigecycline generics starting at $1,200 per vial.
Not supported by the provided prescribing information excerpts.
GoodRx lists branded Tygacil pricing at $2,000+ per vial.
Not supported by the provided prescribing information excerpts.
Coupons can reduce the GoodRx listed price further.
Not supported by the provided prescribing information excerpts.
NeedyMeds and RxAssist connect uninsured or low-income patients to free or low-cost tigecycline via Pfizer outreach.
Not supported by the provided prescribing information excerpts.
Generics from Mylan (now Viatris) and other companies dominate.
Not supported by the provided prescribing information excerpts.
Average wholesale prices are around $1,500–$2,500 per 50 mg vial for generic tigecycline.
Not supported by the provided prescribing information excerpts.
The average wholesale price for Tygacil is $4,000+ per 50 mg vial.
Not supported by the provided prescribing information excerpts.
Hospital bulk discounts often apply.
Not supported by the provided prescribing information excerpts.
No active patents block generics.
Not supported by the provided prescribing information excerpts.
Key U.S. patents expired by 2017.
Not supported by the provided prescribing information excerpts.
Eligibility for assistance programs typically requires U.S. residency.
Not supported by the provided prescribing information excerpts.
Eligibility for assistance programs typically requires no government insurance (e.g., Medicare).
Not supported by the provided prescribing information excerpts.
Eligibility for assistance programs typically requires meeting household income limits.
Not supported by the provided prescribing information excerpts.
Hospitals may negotiate better rates directly.
Not supported by the provided prescribing information excerpts.
Tigecycline demand fluctuates with resistance patterns.
Not supported by the provided prescribing information excerpts.
Eravacycline (Xerava) offers similar broad-spectrum coverage.
Not supported by the provided prescribing information excerpts for tigecycline.
Eravacycline may have lower costs in some settings.
Not supported by the provided prescribing information excerpts.
Oral options like doxycycline are cheaper but less potent for severe cases.
Not supported by the provided prescribing information excerpts.
Contradictions
Important Omissions
No on-label prescribing information elements were addressed by the claims (e.g., boxed warning/all-cause mortality, limitations of use such as not indicated for diabetic foot infections and not indicated for hospital-acquired/ventilator-associated pneumonia, and other warnings/precautions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims reviewed are primarily about pricing/assistance and comparative cost/coverage statements; they do not directly state dosing or safety conclusions tied to the boxed warning or contraindications from the provided label excerpts. However, the lack of labeling-accurate medical content makes on-label guidance verification impossible.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are unrelated to the provided FDA label excerpts (focused on generics/pricing/assistance) and are unsupported by the prescribing information supplied.
Suggested Improvement
Restrict statements to information present in the FDA label excerpts provided (e.g., boxed warning/all-cause mortality, limitations of use for diabetic foot infections and HAP/VAP, and related warnings/adverse reaction context).